3 Promising Penny Stocks With Over $60M Market Cap

As the U.S. stock market experiences a rise following inflation data that met expectations, investors are keenly watching for opportunities across various sectors. Though often seen as relics of past trading days, penny stocks remain relevant today by offering potential growth at lower price points. In this article, we explore three promising penny stocks that showcase financial strength and stability, providing investors with the opportunity to uncover hidden value in quality companies.

Top 10 Penny Stocks In The United States

Click here to see the full list of 375 stocks from our US Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Zenvia (ZENV)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Zenvia Inc. operates a cloud-based platform facilitating integrated communication solutions across multiple countries, with a market cap of $75.31 million.

Operations: The company generates revenue through two primary segments: SaaS, contributing R$325.22 million, and CPaaS, accounting for R$772.32 million.

Market Cap: $75.31M

Zenvia Inc., with a market cap of $75.31 million, operates in the cloud-based communication sector, showing promising revenue streams from its SaaS and CPaaS segments. Despite reporting a net loss of BRL 41.98 million for Q2 2025, it has improved its financial position over time by reducing its debt to equity ratio from 75.5% to 12.5% in five years and maintaining a positive free cash flow with a cash runway exceeding three years. However, challenges remain as short-term liabilities surpass assets and earnings volatility persists above industry norms despite stable weekly volatility over the past year.

• Get an in-depth perspective on Zenvia's performance by reading our balance sheet health report here.
• Gain insights into Zenvia's outlook and expected performance with our report on the company's earnings estimates.

Nautilus Biotechnology (NAUT)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Nautilus Biotechnology, Inc. is a development stage life sciences company focused on creating a platform technology to quantify and understand the complexity of the proteome, with a market cap of $90.95 million.

Operations: As a development stage company, Nautilus Biotechnology has not yet reported any revenue segments.

Market Cap: $90.95M

Nautilus Biotechnology, with a market cap of US$90.95 million, remains pre-revenue, focusing on developing proteome analysis technology. Despite reporting net losses of US$15.03 million for Q2 2025 and US$31.65 million for the first half of the year, its financial health is bolstered by substantial short-term assets (US$150.7M) exceeding liabilities and being debt-free. The company recently entered a strategic alliance with the Allen Institute to explore tau proteins' role in Alzheimer's disease progression, highlighting potential scientific breakthroughs despite projected earnings declines over the next three years and a cash runway extending over two years even if cash flow reduces at historical rates.

• Take a closer look at Nautilus Biotechnology's potential here in our financial health report.
• Gain insights into Nautilus Biotechnology's future direction by reviewing our growth report.

Prelude Therapeutics (PRLD)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Prelude Therapeutics Incorporated is a clinical-stage precision oncology company dedicated to discovering and developing novel cancer medicines for underserved patients, with a market cap of $69.05 million.

Operations: Prelude Therapeutics does not currently report any revenue segments.

Market Cap: $69.05M

Prelude Therapeutics, with a market cap of US$69.05 million, is pre-revenue and focused on developing precision oncology treatments. The company reported a net loss of US$31.23 million for Q2 2025, an improvement from the previous year's loss of US$34.74 million, indicating slight progress in managing expenses. Prelude remains debt-free with short-term assets (US$76.9M) exceeding liabilities, but faces challenges with less than a year of cash runway if current cash flow trends persist. Despite high share price volatility and forecasted earnings declines over the next three years, its experienced management and board offer some stability amidst financial uncertainties.

• Click here and access our complete financial health analysis report to understand the dynamics of Prelude Therapeutics.
• Learn about Prelude Therapeutics' future growth trajectory here.

Turning Ideas Into Actions

• Click here to access our complete index of 375 US Penny Stocks.
• Ready For A Different Approach? These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.